ArticleImmunity, inflammation and disease2026
Concordance Analysis of ALEX-2, ImmunoCAP, and Prick Test for Respiratory Allergies in Lima, Peru.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concordance Analysis of ALEX-2, ImmunoCAP, and Prick Test for Respiratory Allergies in Lima, Peru.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate identification of respiratory allergen sensitization is essential for managing asthma and allergic rhinitis (AR). While Skin Prick Test (SPT) and ImmunoCAP are standard diagnostic tools, exploratory comparative data for the novel Allergy Explorer 2 (ALEX-2) test in Latin American populations remain scarce. While Skin Prick Test (SPT) and ImmunoCAP are standard diagnostic tools with limited allergen panels per test, the novel Allergy Explorer 2 (ALEX-2) multiplex platform can simultaneously assess multiple allergens. However, exploratory comparative data for ALEX-2 in Latin American populations remain scarce.
methodsThis prospective cross-sectional study evaluated the concordance between SPT, ImmunoCAP, and ALEX-2 in detecting respiratory allergen sensitization among 57 patients with asthma or AR recruited consecutively from a private allergy clinic in Lima, Peru. Concordance was assessed using Cohen's κ coefficient.
resultsThe highest overall agreement was observed between ALEX-2 and SPT (κ = 0.5649, p < 0.0001), followed by ALEX-2 and ImmunoCAP (κ = 0.4911, p < 0.0001), and ImmunoCAP and SPT (κ = 0.4688, p < 0.0001). ALEX-2 and ImmunoCAP aligned on 7 of 10 allergens, while both ImmunoCAP and SPT, as well as ALEX-2 and SPT, agreed on 5 of 9 allergens. The strongest concordance was found for dust mites, particularly Dermatophagoides farinae (κ = 0.6323, p < 0.0001) between ALEX-2 and SPT.
conclusionsALEX-2 demonstrates moderate agreement with SPT and ImmunoCAP, with the highest concordance for dust mites, suggesting potential as a complementary diagnostic tool pending validation in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.